A Review on Imiquimod Therapy and Discussion on Optimal Management of Basal Cell Carcinomas
AbstractBasal cell carcinoma (BCC) is the most common type of skin cancer with an increasing incidence. However, it is still poorly researched compared to many other human diseases. Today, cutaneous neoplasms are a frequent, major problem faced by medical professionals. BCC tumors can cause extensive cosmetic distress as well as disfigurement to patients especially when on the face. Treatment options include surgery, systemic agents, and topical agents. Over the past few decades more studies have been performed to evaluate the utility of topical imiquimod therapy for treatment of BCC. Imiquimod is a toll-like receptor that...
Source: Clinical Drug Investigation - August 20, 2018 Category: Drugs & Pharmacology Source Type: research

Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males
ConclusionPharmacokinetic exposure (Cmax and partial AUCs) was dose-proportional over the tested dose range of 0.5 –0.75 µg in healthy Chinese adult males. The pharmacokinetic character of eldecalcitol in Chinese subjects was similar to historical data from Japanese subjects. Eldecalcitol was well tolerated at doses ranging from 0.5 to 0.75 µg, with no new safety signals identified.Clinical Trial RegistrationThis study was registered at the China Food and Drug Administration (Registration number: 2014L02212 and 2014L02213), and also registered athttp://www.chinadrugtrials.org.cn (No. CTR20160430...
Source: Clinical Drug Investigation - August 16, 2018 Category: Drugs & Pharmacology Source Type: research

Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
ConclusionsIclaprim has the potential to reduce the economic burden of acute bacterial skin and skin structure infections in hospitalized patients at risk for vancomycin-associated acute kidney injury when iclaprim acquisition is US$300/day or less. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 13, 2018 Category: Drugs & Pharmacology Source Type: research

A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma
ConclusionIn summary, latent drugs against ovarian serous cystadenocarcinoma were acquired and their target actions and pathways were determined by the network pharmacology strategy, which provides a new prospect for medicamentous therapy for ovarian serous cystadenocarcinoma. However, further in-depth studies are indispensable to increase the validity of this study. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 10, 2018 Category: Drugs & Pharmacology Source Type: research

Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
ConclusionsThe rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF.Trial RegistrationThai Clinical Trial Registry identifier TCTR20141002001. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 1, 2018 Category: Drugs & Pharmacology Source Type: research

Effects of Chronic Carbamazepine Treatment on the ECG in Patients with Focal Seizures
ConclusionOur study shows that chronic use of carbamazepine as monotherapy does not have any significant effects on ECG time intervals or measures of short- and long-term variability. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 25, 2018 Category: Drugs & Pharmacology Source Type: research

Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital
ConclusionsCombining extraction of ICD-10 codes and a focused review of a preselection of relevant hospitalisations appears to be efficient and time-saving. This method should be applied in other hospital settings before considering the exploration of inpatient data on a wider scale. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 25, 2018 Category: Drugs & Pharmacology Source Type: research

Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia
ConclusionAlthough based on a small population, this study represents an unbiased reference on the long-term management of CML in an Italian clinical setting. Our results indicate a better profile of first-line nilotinib, both in terms of persistency and tolerability. AEs remain a major concern, highlighting the importance of close monitoring. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 24, 2018 Category: Drugs & Pharmacology Source Type: research

Patiromer: A Review in Hyperkalaemia
AbstractPatiromer (Veltassa®) for oral suspension is a non-absorbed, sodium-free potassium binding polymer that exchanges calcium for potassium in the gastrointestinal (GI) tract, thereby increasing faecal potassium excretion and reducing serum potassium levels. Patiromer was approved in the USA in 2015 and is now approved in several other countries, including those of the EU, for the treatment of hyperkalaemia in adults. In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart fai...
Source: Clinical Drug Investigation - July 21, 2018 Category: Drugs & Pharmacology Source Type: research

The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol –Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers
ConclusionsAs reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC. Food had no effect on tramadol orO-desmethyltramadol bioavailability.Clinical trial registration number152052 (registered with the Therapeutic Products Directorate of Health Canada) (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 14, 2018 Category: Drugs & Pharmacology Source Type: research

Gadobutrol: A Review in Contrast-Enhanced MRI and MRA
AbstractIntravenous gadobutrol [Gadovist™ (EU); Gadavist® (USA)] is a second-generation, extracellular non-ionic macrocyclic gadolinium-based contrast agent (GBCA) that is approved for use in paediatric (including term neonates) and adult patients undergoing diagnostic contrast-enhanced (CE) MRI for visualization of pathological lesions in all body regions or for CE MRA to evaluate perfusion and flow-related abnormalities. Its unique physicochemical profile, including its high thermostability and proton relaxation times, means that gadobutrol is formulated at twice the gadolinium ion concentration of other GBCAs,...
Source: Clinical Drug Investigation - July 13, 2018 Category: Drugs & Pharmacology Source Type: research

Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects
ConclusionsA single intravenous injection of r-batroxobin within a dose range of 2.5 –10.0 BU/2.0 mL was well tolerated and resulted in a significant decrease in fibrinogen and prolongation of TT.RegistrationThis study is registered at the Clinical Research Information Service (CRIS,http://cris.nih.go.kr), number KCT0002518. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 5, 2018 Category: Drugs & Pharmacology Source Type: research

Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab
ConclusionThe study outcomes indicate that ustekinumab could be safe for psoriasis patients since none developed persistent hepatitis or acute liver failure during therapy. However, the re-appearance of plasma HBV DNA requires appropriate monitoring of HBV viral load during ustekinumab treatment. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 2, 2018 Category: Drugs & Pharmacology Source Type: research

Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
In this study, we investigated the effect of TKIs on the levels of plasma TPO concentration in patients with well-controlled chronic myeloid leukemia receiving imatinib or dasatinib and those in treatment-free remission (TFR).MethodsBlood samples for blood cell counts and plasma TPO levels were obtained from 23 dasatinib-treated patients before and 1 h after intake, 11 patients treated with imatinib before and 2  h after intake, and nine TFR patients. Levels of plasma TPO were determined by using enzyme-linked immunosorbent assays.ResultsLevels of TPO were significantly inversely correlated with platelet counts in the...
Source: Clinical Drug Investigation - June 25, 2018 Category: Drugs & Pharmacology Source Type: research

Budget Impact Analysis of Oral Fisiogen Ferro Forte ® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain
ConclusionsThe increase in the use of Fisiogen Ferro Forte® leads to overall budget savings of €775,464 for the Spanish National Health Service over 4 years. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 22, 2018 Category: Drugs & Pharmacology Source Type: research

Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
AbstractIntroductionPublished literature on overdoses related to botulinum toxin A (BtxA) agents is scarce.ObjectiveThe aim of this study was to assess the BtxA drug class ’ respective agents for associations with overdose.MethodsUnited States Food and Drug Administration (FDA) adverse event reporting system (FAERS) database was utilized to search for overdoses. The analysis was conducted on data between second quarter 2014 and third quarter 2017. BtxA cases were included when they were considered the “Primary Suspect” drug. Overdose was defined as presence of ‘overdose’ being reported as an a...
Source: Clinical Drug Investigation - June 20, 2018 Category: Drugs & Pharmacology Source Type: research

Correction to: Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data
In the original publication, the Estimate column with values under Multivariate meta-regression (LOCF) in Table  1 was missed. The corrected table is shown below. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 19, 2018 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Na ïve Participants: Results of a Phase 1, Multiple Ascending Dose Study
ConclusionDose-dependent fentanyl pharmacokinetics following multiple doses of fentanyl sublingual spray were well characterized in an opioid-na ïve population.ClinicalTrials.gov identifierNCT02641340. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 16, 2018 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men
ConclusionsIn healthy men, sublingual and supralingual administration of sildenafil ODF resulted in a remarkably similar pharmacokinetic profile and confirmed the safety of both study treatments. The recently marketed sildenafil ODF, administered by both investigated routes, can provide a valuable alternative to the marketed solid oral forms (tablets) in ED treatment. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 16, 2018 Category: Drugs & Pharmacology Source Type: research

Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza ® ER and Other ER Opioid Formulations”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 12, 2018 Category: Drugs & Pharmacology Source Type: research

Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza ® ER and Other ER Opioid Formulations
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 12, 2018 Category: Drugs & Pharmacology Source Type: research

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
AbstractBackground  and ObjectiveVerinurad (RDEA3170) is a high-affinity, selective URAT1 transporter inhibitor in development for treating gout and asymptomatic hyperuricemia. This Phase I, single-dose study investigated the pharmacokinetics, pharmacodynamics, and safety of verinurad in adults with renal impairment and controls with normal renal function.MethodsMales aged 18 –85 years were enrolled with serum urate (sUA) 4.5–10 mg/dl and creatinine clearance 60– 
Source: Clinical Drug Investigation - June 11, 2018 Category: Drugs & Pharmacology Source Type: research

Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
ConclusionPatients with schizophrenia, irrespective of prior treatment with RIS/PALI, had comparable treatment outcomes and tolerability following PP3M or PP1M treatment.RegistrationThis study is registered at the EU clinical trial registry (EudraCT Number: 2011-004889-15) and ClinicalTrials.gov (identifier: NCT01515423). (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 7, 2018 Category: Drugs & Pharmacology Source Type: research

Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data
ConclusionPlacebo response in schizophrenia clinical trials published between 2007 and 2016 has not increased over time. Differences in the healthcare environment among countries were suggested to affect the evaluation of antipsychotic drugs. Further analyses on the potential factors of placebo response for MMRM-based data are required. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 1, 2018 Category: Drugs & Pharmacology Source Type: research

Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies
ConclusionNo drug recommendation achieved an “Excellent” quality of evidence. Limited data suggest that clinicians should consider each individual class of medication when selecting a dose for obese surgical patients. Routine use of fixed-dosing regimens is likely to under- or overdose obese patients thus predisposing them to adverse drug events or treatment failure leading to patient harm. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 1, 2018 Category: Drugs & Pharmacology Source Type: research

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
ConclusionsPharmacokinetic properties support both morning and evening dosing. BI 425809 was generally well tolerated at all tested doses.Clinicaltrials.gov identifierNCT02337283. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 30, 2018 Category: Drugs & Pharmacology Source Type: research

The Utility of 5 Hypothetical Health States in Heart Failure Using Time Trade-Off (TTO) and EQ-5D-5L in Korea
AbstractBackground and ObjectiveUtility provides a preference for specific health state in economic evaluation, and they obtained from general population could be useful in respect of societal resource allocation. We aimed to investigate the utilities of health states for heart failure (HF), a major and growing public health problem, related to hospitalization and adverse drug effects by interrogating the general Korean population.MethodsFive health states for patients with HF were developed based on literature reviews: stable chronic heart failure (SCHF), hospitalization, SCHF  + cough, SCHF + ...
Source: Clinical Drug Investigation - May 26, 2018 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
ConclusionPLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 9, 2018 Category: Drugs & Pharmacology Source Type: research

Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review
AbstractThe process of finding new therapeutic indications for currently used drugs, defined as ‘repurposing’, is receiving growing attention. Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple’s disease, fungal infections), rheumatological (systemic lupus erythematosus , antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren’s syndrome), and other immunological diseases. Indeed, they have anti-inflammatory, immunomodulating, anti-infective, antithrombotic, and meta...
Source: Clinical Drug Investigation - May 8, 2018 Category: Drugs & Pharmacology Source Type: research

Acetazolamide and Cardiac Failure
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 7, 2018 Category: Drugs & Pharmacology Source Type: research

Response to “Acetazolamide and Cardiac Failure”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 7, 2018 Category: Drugs & Pharmacology Source Type: research

Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of  Five Eastern Asian Countries
ConclusionTreatment of ACS for 12  months with ticagrelor is not a cost-effective option for the prevention of thrombotic events in East Asia. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 30, 2018 Category: Drugs & Pharmacology Source Type: research

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men
ConclusionsSuvorexant was generally well tolerated after single and multiple dosing for 14  days. The findings support the once-nightly dosing regimen. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 28, 2018 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment
ConclusionACL/FF 400/12  µg was a cost-saving therapy in patients with moderate-to-severe COPD in Spain, and provided equivalent effects compared to TIO/OLO 5/5 µg. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 13, 2018 Category: Drugs & Pharmacology Source Type: research

Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
AbstractThe US Food and Drug Administration (FDA) is encouraging the innovation of long-acting opioid formulations that are manipulation-resistant. The purpose of this commentary is to assess the benefits and limitations of abuse-deterrent opioid formulations (ADFs) and discuss their role in mitigating the current opioid epidemic. ADFs have been created with chemical properties that make it difficult for people who non-medically use prescription drugs to crush and dissolve opioid tablets, as well as by combining opioids with antagonists such as naloxone or naltrexone, which are released only when the dosage form has been m...
Source: Clinical Drug Investigation - April 12, 2018 Category: Drugs & Pharmacology Source Type: research

Impact of Anthracyclines on Diabetes Mellitus  Development in B-Cell Lymphoma Patients: A Nationwide Population-based Study
ConclusionAnthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients. Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 9, 2018 Category: Drugs & Pharmacology Source Type: research

Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting
AbstractDrug utilization research on benzodiazepines remains important for measuring trends in consumption within and across borders over time for the sake of monitoring prescribing patterns and identifying potential population safety concerns. The defined daily dose (DDD) system by the World Health Organization (WHO) remains the internationally accepted standard for measuring drug consumption; however, beyond consumption, DDD-based results are difficult to interpret when individual agents are compared with one another or are pooled into a total class-based estimate. The diazepam milligram equivalent (DME) system provides ...
Source: Clinical Drug Investigation - April 4, 2018 Category: Drugs & Pharmacology Source Type: research

Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease
ConclusionsBetter adherence to antidepressants is associated with reduced all-cause mortality, mainly in patients who did not use other pharmacological treatments. Behavioural changes to enhance adherence among the elderly with cardiovascular disease might offer important benefits in reducing their mortality. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 27, 2018 Category: Drugs & Pharmacology Source Type: research

Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick ® ): A Review in Asthma
AbstractThe novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick®) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting β2-adrenoreceptor agonist (LABA) combination treatment is available in low-, mid- and high-dosage formulations (55/14, 113/14 and 232/14  μg, respectively). In 12-week, phase III trials in patients aged ≥ 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment pr...
Source: Clinical Drug Investigation - March 26, 2018 Category: Drugs & Pharmacology Source Type: research

Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males
AbstractBackground and objectivesG protein-coupled receptor 119 (GPR119) agonists reduce plasma glucose by promoting insulin secretion in a glucose-dependent manner. We evaluated the safety and pharmacokinetics of multiple oral doses of DS-8500a, a GPR119 agonist, under fed conditions in healthy adult Japanese male subjects.MethodsIn this Phase 1, randomized, placebo-controlled, double-blind, multiple oral dose study, participants were aged ≥ 20 and ≤ 45 years with a body mass index ≥ 18.5 and
Source: Clinical Drug Investigation - March 26, 2018 Category: Drugs & Pharmacology Source Type: research

Retraction Note to: Efficacy of Menatetrenone (Vitamin K2) against Non-Vertebral and Hip Fractures in Patients with Neurological Diseases
AbstractThe Editor-in-Chief has retracted this article because two of the three studies [1,2] included in the meta-analysis (cited as references 11 and 12) have been retracted due to fabrication of the data, which has rendered the results of this meta-analysis invalid. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 26, 2018 Category: Drugs & Pharmacology Source Type: research

Interventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviews
ConclusionFindings from this overview support the superiority of NOACs and patient ’s self-management for preventing stroke in AF patients. However, uncertainties remain on the benefits of genotype-guided dosing and pharmacist-managed anticoagulation clinics due to poor quality evidence, and future research is warranted. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 22, 2018 Category: Drugs & Pharmacology Source Type: research

Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis
ConclusionThe 2008 FDA guidance appears to have a positive impact on CV risk assessment of recently marketed drugs for the management of diabetes. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 21, 2018 Category: Drugs & Pharmacology Source Type: research

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
ConclusionsThese observations suggest that pixantrone monotherapy in patients with multiply relapsed or refractory aggressive NHL who had received at least two prior therapies can be associated with durable responses and long-term remission, and this may be unrelated to the clinical response to the last therapy. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 21, 2018 Category: Drugs & Pharmacology Source Type: research

Review of West Syndrome: Concerns on Optimum Dose of Adrenocorticotrophic Hormone
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 19, 2018 Category: Drugs & Pharmacology Source Type: research

The Impact of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Intestinal Microbiota Differs from that of Laparoscopic Sleeve Gastrectomy in Japanese Patients with Obesity
ConclusionsLSG and LSG-DJB improved obesity and type 2 diabetes in Japanese patients with obesity, but the impact of LSG-DJB on the intestinal microbiota differed from that of LSG. This difference in the impact on the intestinal environment could explain the different efficacies of LSG and LSG-DJB in terms of their ability to resolve metabolic disorders in the clinical setting. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 5, 2018 Category: Drugs & Pharmacology Source Type: research

Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit
ConclusionDexmedetomidine, used as a single sedative, may have contributed to a shorter weaning period than SOC or SOCDEX. Patients who received dexmedetomidine-only sedation tended to report better health-related quality of life than those receiving other forms of sedation. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 3, 2018 Category: Drugs & Pharmacology Source Type: research

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
AbstractBiosimilars are biological medicines that are approved via stringently defined regulatory pathways on the basis that comparable safety, efficacy, and quality have been demonstrated to their reference medicine. The advantage of biosimilar drugs is that they may be less expensive than the reference medicine, allowing for greater patient access and cost savings in already stretched healthcare budgets. Biosimilar epoetins have been available in Europe for a decade. Complementingin vitro and preclinical characterization, and pharmacokinetic/pharmacodynamic studies, clinical trials provided the additional data needed to ...
Source: Clinical Drug Investigation - March 2, 2018 Category: Drugs & Pharmacology Source Type: research

Reply to Braillon et al.:  Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 26, 2018 Category: Drugs & Pharmacology Source Type: research

Retraction Note to: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting
The Editor-in-Chief has retracted the original article [1] because a number of studies [2 –15] included in this review (cited as references 25-29, 31, 32, 47, 48, 50-54) have been retracted, specifically those included in table III, table IV, section 3 and section 4.2. This has rendered the content of the review scientifically unreliable. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 26, 2018 Category: Drugs & Pharmacology Source Type: research